Clinical trials: Pulmonary Sarcoidosis
Sarcoidosis, Pulmonary
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).
- Trial name
- RESOLVE-Lung (NCT05314517)
- Testing
- Namilumab
- Where
- 47 sites in United States, Belgium and 5 more
- Volunteers
- 107 people
- Sponsor
- Kinevant Sciences GmbH
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia
- Trial name
- NCT02036970
- Testing
- Bardoxolone methyl
- Where
- 32 sites in United States, Germany
- Volunteers
- 166 people
- Sponsor
- Biogen
Pulmonary Sarcoidosis
Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
The purpose of this proof of concept study was to determine whether CMK389 displays the safety and efficacy profile to support further development in chronic pulmonary sarcoidosis.
- Trial name
- NCT04064242
- Testing
- CMK389
- Where
- 22 sites in United States, Czechia and 4 more
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Sarcoidosis-associated Pulmonary Hypertension
A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
Oral selexipag is commercially available in several countries for the treatment of a particular group of pulmonary hypertension (PH) called pulmonary arterial hypertension (PAH).
- Trial name
- SPHINX (NCT03942211)
- Testing
- Selexipag
- Where
- 38 sites in United States, Belgium and 8 more
- Volunteers
- 10 people
- Sponsor
- Actelion
Pulmonary Sarcoidosis
Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK), and preliminary efficacy of multiple ascending doses of IV efzofitimod…
- Trial name
- NCT03824392
- Where
- 15 sites in United States
- Volunteers
- 37 people
- Sponsor
- aTyr Pharma, Inc.
Sarcoidosis, Pulmonary
Acthar Gel in Participants With Pulmonary Sarcoidosis
The purpose of this study is to find out if Acthar Gel is safe and effective to treat pulmonary sarcoidosis. Participants will be randomly assigned (like flipping a coin) to receive a shot under their skin of Acthar Gel or a…
- Trial name
- PULSAR (NCT03320070)
- Testing
- Acthar Gel
- Where
- 29 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mallinckrodt
Sarcoidosis, Pulmonary, Sarcoidosis Lung
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
This is a pilot study to determine whether further research is warranted to assess whether tofacitinib is an effective steroid sparing treatment for pulmonary sarcoidosis.
- Conditions
- Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
- Trial name
- NCT03793439
- Testing
- Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Oregon Health and Science University
Pulmonary Sarcoidosis
Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.
- Trial name
- NCT02888080
- Testing
- ACZ885
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Sarcoidosis
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
This is a pilot study investigating the effect of an antioxidant, N-Acetyl-L-Cysteine (NAC), on inflammation and oxidative stress in sarcoidosis.
- Trial name
- NCT01587001
- Testing
- N-acetyl-cysteine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Jewish Health
Pulmonary Sarcoidosis
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis
The study proposes to evaluate the safety, tolerability, and efficacy of PD 0360324 in subjects with chronic pulmonary sarcoidosis inadequately treated with standard of care therapies.
- Trial name
- NCT01732211
- Testing
- PD 0360324, Normal Saline for injection
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Emphysema, Chronic Obstructive Pulmonary Disease (COPD)
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
The purpose of this research study is to learn about the safety of transplanting lungs obtained from non-heart-beating donors (NHBDs) that have been ventilated (attached to a breathing machine or ventilator to deliver oxygen) and…
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- NCT01615484
- Testing
- Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill
Sarcoidosis, Pulmonary
Atorvastatin to Treat Pulmonary Sarcoidosis
This study will determine if atorvastatin (Lipitor) can help patients with pulmonary (lung) sarcoidosis and replace or reduce the need for patients to take steroids, such as prednisone.
- Trial name
- NCT00279708
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lung Diseases, Obstructive, Sarcoidosis
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
The purpose of this study is to evaluate the safety, effectiveness, and side effects of the CryoSpray AblationTM System (CryoSpray AblationTM, "CSA" or "cryospray therapy") to treat benign airway disease in the lung using liquid…
- Conditions
- Lung Diseases, Obstructive, Sarcoidosis, Wegener's Granulomatosis, Rhinoscleroma
- Trial name
- ICEtheBAD (NCT00747461)
- Testing
- CryoSpray Ablation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- CSA Medical, Inc.
Sarcoidosis
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
This study tests the safety and effectiveness of ustekinumab or golimumab compared to placebo (placebo looks like the drugs being studied, but has no active ingredients).
- Trial name
- NCT00955279
- Testing
- Golimumab, Ustekinumab
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 173 people
- Sponsor
- Centocor, Inc.
Pulmonary Sarcoidosis, Lung Function
Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis
Sarcoidosis is a granulomatous disease for which the molecular and immunologic association with mycobacteria continues to strengthen.
- Trial name
- CLEAR Lung (NCT01169038)
- Testing
- levaquin; ethambutol; rifampin and azithromycin.
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Vanderbilt University